Systematic Review

Placenta Accreta Spectrum Disorder Complicated with Endometriosis: Systematic Review and Meta-Analysis

Shinya Matsuzaki 1,2,*, Yutaka Ueda 2, Yoshikazu Nagase 2, Satoko Matsuzaki 3, Mamoru Kakuda 2, Sahori Kakuda 1, Hitomi Sakaguchi 1,2, Tsuyoshi Hisa 1 and Shoji Kamiura 1

1 Department of Gynecology, Osaka International Cancer Institute, Osaka 541-8567, Japan; saho_y19@yahoo.co.jp (S.K.); hitomi.sakaguchi@oici.jp (H.S.); hisa-tu@mc.pref.osaka.jp (T.H.); kamiura-sh@oici.jp (S.K.)
2 Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; y.ueda@gyne.med.osaka-u.ac.jp (Y.U.); yna.nagase@gyne.med.osaka-u.ac.jp (Y.N.); mamorukakuda@gyne.med.osaka-u.ac.jp (M.K.)
3 Department of Obstetrics and Gynecology, Osaka General Medical Center, Osaka 558-8558, Japan; satoko_tsuru@yahoo.co.jp

* Correspondence: zacky@gyne.med.osaka-u.ac.jp; Tel.: +81-6-6879-3355

Abstract: This study aimed to assess the relationship between placenta accreta spectrum disorder (PASD) and endometriosis. The relationships among pregnancy, assisted reproductive technology (ART), placenta previa, ART-conceived pregnancy and PASD were also determined. A systematic literature review was conducted using multiple computerized databases. Forty-eight studies (1990–2021) met the inclusion criteria. According to the adjusted pooled analysis \((n = 3)\), endometriosis was associated with an increased prevalence of PASD (adjusted odds ratio [OR] 3.39, 95% confidence interval [CI] 1.96–5.87). In the included studies, the ART rate ranged from 18.2% to 37.2% for women with endometriosis. According to the adjusted pooled analysis, women who used ART were more likely to have placenta previa \((n = 13): \text{adjusted OR} 2.96, 95\%CI 2.43–3.60)\) and PASD \((n = 4): \text{adjusted OR} 3.54, 95\%CI 1.86–6.76)\) than those who did not use ART. According to the sensitivity analysis using an unadjusted analysis accounting for the type of ART, frozen embryo transfer (ET) was associated with an increased risk of PASD \((n = 4): \text{OR} 2.79, 95\%CI 1.22–6.37)\) compared to fresh ET. Endometriosis may be associated with an increased rate of PASD. Women with placenta previa complicated with endometriosis who conceived using frozen ET may be a high risk for PASD.

Keywords: placenta accreta spectrum; endometriosis; pelvic adhesion; assisted reproductive technology; systematic review

1. Introduction

For women with placenta accreta spectrum disorder (PASD), massive hemorrhage is a severe complication, with intraoperative blood loss possibly exceeding several liters and leading to disseminated intravascular coagulation and, ultimately, maternal death [1–4]. There is also a high risk of bladder injury and ureter injury; therefore, cesarean hysterectomy without any attempt to remove the placenta is often required to avoid these complications [2,5–7]. Endometriosis is a frequent benign gynecologic disease wherein endometrial-like glands and stroma grow outside the uterus [8,9].

The estimated incidence of endometriosis in women of reproductive age is around 5–15%, and endometriosis may be increasing in pregnant women [10–13]. Moreover, live birth rates have improved with assisted reproductive technology (ART) and previous studies have shown that 25–50% of infertile women suffer endometriosis [10–14].

Pregnant women with endometriosis are more likely to use ART to conceive than those without endometriosis; however, ART-conceived pregnancies are associated with an increased prevalence of PASD [15]. Furthermore, recent systematic reviews have reported...
that women with endometriosis are more likely to have placenta previa than those without endometriosis. Placenta previa involves a high risk of postpartum hemorrhage, and approximately half of all placenta previa cases result in postpartum hemorrhage [16]. Additionally, placenta previa is associated with an increased rate of PASD and is the most significant risk factor for PASD [17]. Therefore, it is possible that women with endometriosis have a higher prevalence of PASD than those without endometriosis [14,18,19]. Previous studies have shown that women with endometriosis who underwent gynecologic surgery have had increased rates of ureteral injury and prolonged operative times compared to those without endometriosis [20,21].

As shown in Supplemental Figure S1 [22–26], women with endometriosis who have PASD often have extraterine posterior adhesions, thus making it difficult to exteriorize the uterus. Based on our experience, women with PASD and endometriosis have poor surgical outcomes because of the difficulty of cesarean hysterectomy. Therefore, we believe that endometriosis may be correlated with adverse surgical outcomes of women with placenta previa and PASD. Recently, endometriosis has been consistently found to be associated with an increased risk of placenta previa [27,28]. Although the association between endometriosis and an increased risk of placenta previa is robust [22–26], the association between PASD and endometriosis is unclear. Moreover, the surgical outcomes of women with PASD complicated with endometriosis are unclear.

We performed a systematic review of computerized databases from their inception to 31 October 2021. This study aimed to assess the effect of endometriosis on the incidence of PASD. Since women with endometriosis often conceive using ART, we also determined the effect of ART on the prevalence of placenta previa and PASD. If no studies regarding the outcome of interest were identified during our systematic review, then a narrative review or our opinion about the topic regarding pregnant women with endometriosis was used.

2. Materials and Methods

Since endometriotic lesions are difficult to diagnose in pregnant women, the current study identified endometriosis in pregnant women with the following criteria [29]: (i) histologically confirmed endometriosis; (ii) endometriosis diagnosed by clinical findings (e.g., ultrasound, pelvic adhesions, posterior uterine wall adhesions, or the existence of an endometriotic cyst); (iii) endometriosis suspected clinically or histopathologically during cesarean delivery; and (iv) women identified with endometriosis by using the International Classification of Diseases code. Severe endometriosis was defined as deep infiltrating endometriosis or revised American Society for Reproductive Medicine stage III or IV endometriosis.

2.1. Systematic Literature Review

A systematic literature search was performed to examine the effect of endometriosis on the incidence of PASD. The same search terms used for endometriosis during our previous systematic review were used during this study (Supplemental File S1) [29]. The outcomes of interest during this study were as follows: (i) the effect of endometriosis on the prevalence of PASD; (ii) the effect of endometriosis on surgical outcomes of patients with placenta previa and endometriosis; (iii) the effect of ART on the incidence of placenta previa; (iv) the influence of ART on the PASD rate.

In compliance with the 2020 edition of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement [30], a systematic literature search was performed using PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus from their inception to 31 October 2021, using Medical Subject Headings (MeSH terms) (if applicable) and words related to placenta previa complicated by endometriosis. This systematic review was not pre-registered.
2.2. Eligibility Criteria, Information Sources, and Search Strategy

Studies were screened by checking the titles and abstracts of relevant articles, as previously described [31–33]. All abstracts were screened by the authors (Sh.M. and Sa.M.) using the MeSH terms and the PubMed and Cochrane databases to identify studies that examined the following associations: endometriosis and PASD; ART and placenta previa; ART and PASD (Supplemental File S1).

2.3. Study Selection

Studies were included if they met the following criteria: (i) comparative study was performed that examined the outcomes of interest between an experimental group and a control group (e.g., comparison of women with and without endometriosis, ART versus spontaneous conception, frozen embryo transfer [ET] versus fresh ET, etc.); (ii) endometriosis as defined according to this study; (iii) pelvic adhesions caused by suspected endometriosis (most patients had a histopathological or clinical diagnosis); (iv) the influence of endometriosis on the prevalence of PASD was determined; (v) surgical outcomes of women with endometriosis complicated by PASD were discussed; (vi) the association between ART and placenta previa was examined; and (vii) the effect of ART on the frequency of PASD was determined.

The exclusion criteria were as follows: (i) insufficient information to clearly identify the outcomes of interest; (ii) the definition of endometriosis was unclear or did not meet the definition used by this study; (iii) patients’ background were restricted (e.g., cases were restricted to women with prior cesarean delivery, or polycystic ovary syndrome, or oocyte donation, etc.); (iv) non-English articles; (v) and case reports, conference abstracts, case series, reviews, systematic reviews, and meta-analyses.

2.4. Data Extraction

All data were extracted by the author (Sh.M.). The year of the study, first author’s name, study location, number of included cases, definition of endometriosis, and outcomes of interest were recorded. The data to be included in the analysis were verified by another author (Y.N.).

2.5. Analysis of Outcome Measures and Assessment of Bias Risk

The primary aims of this review were to focus on the clinical research surrounding PASD complicated with endometriosis and to focus on the studies assessing the effect of ART on the prevalence rates of placenta previa and PASD. The primary outcome was the surgical outcomes of women with endometriosis complicated by PASD. The secondary aims of this study were as follows: (i) to determine the estimated prevalence of PASD for patients with endometriosis; (ii) to determine the effect of endometriosis on the diagnosis of PASD; (iii) and to determine the proposed surgical technique for endometriosis patients with PASD during cesarean delivery.

Risk of bias assessment was performed using the Risk Of Bias In Non-randomized Studies-of Interventions tool (ROBINS-I) as previously described [34–36].

2.6. Meta-Analysis

Hazard ratios by using 95% confidence intervals (CIs) and odds ratios (ORs) were calculated with the outcomes of interest. Study heterogeneity was analyzed using the $I^2$ statistic to determine the total deviation percentage among studies. In accordance with the Cochrane Handbook for Systematic Reviews of Interventions (version 6.0), heterogeneity was determined based on the $I^2$ value as: low heterogeneity ($I^2$: 0–30%); moderate heterogeneity ($I^2$: 30–60%); substantial heterogeneity ($I^2$: 50–90%); and considerable heterogeneity ($I^2$: 75–100%) [37].

A meta-analysis was also performed. All graphics were constructed using RevMan version 5.4.1 software (Cochrane Collaboration, Copenhagen, Denmark). During the pooled
analysis, a fixed-effects model was used for low heterogeneity, and a random-effects model was used for moderate to considerable heterogeneity.

2.7. Statistical Analysis

The chi-squared test or Fisher’s exact test was used to analyze differences in patients’ characteristics between the experimental and control groups. All statistical analyses were based on two-sided hypotheses. A $p$-value < 0.05 was considered statistically significant [38]. The SPSS version 28.0 (IBM Corp., Armonk, NY, USA) was used in the analyses.

3. Results

Figure 1 illustrates the study selection scheme. Overall, 1175 studies were examined. Four studies were excluded due to the presence of overlapping cases [39–42]. Forty-eight studies that comprised 34,603,164 pregnancies and 59,241 pregnancies with endometriosis met the inclusion criteria for the descriptive analysis [26,27,43–88].

![Figure 1. Study selection scheme of the systematic search of articles. Abbreviations: PP, placenta previa, PASD, placenta accreta spectrum disorder.](image)

3.1. Study Characteristics

Supplemental Tables S1–S4 summarizes the metadata of the 48 included studies [26,27,43–88] and 4 excluded studies [39–42]. The included studies were published between 1990 and 2021, and all studies were retrospective ($n = 48$). Fourteen of 48 studies were nationwide studies, and no study was a randomized, controlled study. Approximately one-third of the studies were performed in Europe ($n = 17$; 35.4%) [27,46,48,53,54,57,60,62,64,70–73,77,79,83,86], followed by Japan ($n = 11$; 22.9%) [26,52,55,56,58,59,68,74,81,82,88], China ($n = 10$; 20.8%) [43,45,47,49,61,66,67,69,78,80], the United States ($n = 4$; 8.3%) [50,51,75,87], Israel ($n = 2$; 4.2%) [63,84], Australia ($n = 2$; 4.2%) [76,85], Canada ($n = 1$; 2.1%) [65], and Iran ($n = 1$; 2.1%) [44].

3.1.1. Risk of Bias of Included Studies

The risk of bias assessment for the comparative studies is shown in Supplemental Table S5. Of those ($n = 48$), a possible moderate publication bias (moderate quality) in 36 studies and severe publication bias (low quality) in the other 12 studies were observed.
3.1.2. Number of Studies: Primary Outcome

A systematic literature search was performed to identify studies that included the outcomes of interest. There were four regarding the effect of endometriosis on the prevalence of PASD. There were zero studies regarding the effect of endometriosis on the surgical outcomes of patients with PASD and endometriosis. There were 27 studies regarding the effect of ART on the rate of placenta previa. There were 15 regarding the influence of ART on the incidence of PASD.

3.1.3. Number of Studies: Secondary Outcome

There was one study regarding the estimated prevalence of PASD for patients with endometriosis. There were zero studies regarding the effect of endometriosis on the diagnosis of PASD. There were zero studies regarding the proposed surgical technique for endometriosis patients with PASD during cesarean hysterectomy. Only one study regarding the secondary outcomes of this study was identified.

3.2. Epidemiology and Outcomes

3.2.1. Prevalence of PASD with Endometriosis

We performed a systematic literature search of the epidemiology of patients with PASD and endometriosis. During this analysis, only nationwide studies were included. To date, only one study performed in Europe has examined the prevalence of PASD for women with endometriosis during pregnancy [27]. A study by Berlac indicated that 7 of 73,272 (0.01%) women had endometriosis with PASD [27]. To discuss this topic, we added a narrative review of the prevalence of PASD for the general population.

3.2.2. Population-Based Prevalence of PASD for the General Population

Recently, several studies have examined the prevalence of PASD for the general population (Table 1) [17,56,89–92]. The estimated overall prevalence of PASD reported by these studies varied from 0.05% to 0.84%. Nevertheless, some nationwide studies support the notion that the prevalence of PASD is increasing [17,91]. Regarding the prevalence of endometriosis during pregnancy, two nationwide studies have shown rates of 0.9% [48] and 1.8% [27]. These results suggest that PASD complicated with endometriosis is rare.

Table 1. The prevalence and trends of PASD.

| Author          | Year | Location | Type     | PASD No. | Total No. | Rate    | Trend  | Definition |
|-----------------|------|----------|----------|----------|-----------|---------|--------|------------|
| Ornaghi S [89]  | 2021 | ITA      | Nationwide | 384     | 458,995  | 0.84%   | –      | Clinical   |
| Matsuzaki S [17]| 2021 | USA      | Nationwide | 8030   | 2,727,477 | 0.29%   | Increase| ICD-10    |
| Miller HE [90]  | 2021 | USA      | Nationwide | 1126   | 918,452  | 0.12%   | –      | ICD-10    |
| Baldwin HJ [91] | 2020 | AUS      | Nationwide | 3300   | 1,306,308 | 0.25%   | Increase| ICD-10    |
| Kyozuka H [56]  | 2019 | JPN      | Nationwide | 202    | 90,554   | 0.22%   | –      | Clinical   |
| Jauniaux E [92] | 2019 | GBR      | SR       | 20 studies | –       | 0.05–0.42% | –      | –         |

* Restricted to women with cesarean deliveries, † Number of births. Abbreviations: Type, type of study; PASD No., number of women with placenta accreta spectrum disorder; Total No., number of total cases; Rate, rate of placenta accreta spectrum disorders; Definition, definition of placenta accreta spectrum disorder: Nationwide, Nationwide study; SR, systematic review; Clinical, clinical diagnosis; ICD-10, International Classification of Diseases 10th Revision; ITA, Italy; USA, United States of America; AUS, Australia; JPN, Japan; GBR, United Kingdom.

Although we believe that these studies are useful for estimating the prevalence of PASD for women with endometriosis, it should be noted that the accuracy of the diagnosis of endometriosis with PASD is unclear in nationwide studies (all studies identified eligible patients using diagnostic codes or clinical diagnosis). Therefore, future studies examining the nationwide prevalence of PASD for women with endometriosis with an accurate diagnosis are warranted.
3.3. Primary Outcome: Association between Endometriosis and PASD

We identified four comparator studies with moderate quality that examined the effect of endometriosis on the prevalence of PASD (Table 2) [27,47,63,64]. Of those four studies, one was a population-based study and three were retrospective studies. Furthermore, among those four studies, three clarified the definition of endometriosis and one clarified the definition of PASD. According to the unadjusted, pooled, random-effects analysis, endometriosis was associated with an increased rate of PASD (Figure 2A) \( (n = 4, \text{OR} = 3.97, 95\%\text{CI} = 1.30–12.11; \text{heterogeneity: } p = 0.02, I^2 = 70\% ) \). According to the adjusted, pooled, fixed-effects analysis, endometriosis was associated with an increased prevalence of PASD (Figure 2B) \( (n = 3, \text{OR} = 3.39, 95\%\text{CI} = 1.96–5.87; \text{heterogeneity: } p = 0.34, I^2 = 8\% ) \).

Some values listed might be slightly different from the original values because the calculation was performed using RevMan version 5.4.1 or they were estimated by the authors. Abbreviations: OR, odds ratio; cOR, crude odds ratio; aOR, adjusted odds ratio; –, not applicable; ART, assisted reproductive technology; CI, confidence interval; Def_End, the definition of endometriosis; Def_PASD, the definition of placenta accreta spectrum disorder; Clinical, clinical diagnosis; Histo, histologically confirmed endometriosis; ICD-10, International Classification of Diseases 10th Revision.

![Figure 2. Effect of endometriosis on the prevalence of placenta accreta spectrum disorder.](image-url)
3.4. Primary Outcome: Association between ART and Placenta Previa

A meta-analysis using 27 comparative retrospective studies (7 of low and 20 of moderate quality) was conducted to determine the influence of ART on the prevalence of placenta previa (Supplemental Table S2, Table 3) [26,43,47–49,51–55,57,60–62,65–67,69,72,73,78,79,82,85–88]. Since considerable heterogeneity of studies was observed, a random-effects analysis was used. According to the unadjusted pooled analysis \( (n = 27) \), women who conceived using ART were more likely to have placenta previa than those who conceived without ART (Figure 3A) (OR 3.47, 95%CI 2.74–4.39; heterogeneity: \( p < 0.01, I^2 = 99\% \)).

During the adjusted pooled analysis, we performed a random-effects analysis for considerable heterogeneity. The results of this study were similar to those of the unadjusted analysis (Figure 3B) (OR 2.96, 95%CI 2.43–3.60; heterogeneity: \( p < 0.01, I^2 = 92\% \)) of women with endometriosis and women without endometriosis [26,27,48,63,66,68,70,81,85,93–95]. Based on the results of these studies, ART-conceived pregnancy was associated with a significantly increased rate of placenta previa.

| Author          | Year | Exp      | Control     | cOR (95%CI) | aOR (95%CI)  |
|-----------------|------|----------|-------------|-------------|--------------|
| Wang Y [43]     | 2021 | ART      | No ART      | 2.41 (2.36–2.45) | –            |
| Wang J [47]     | 2021 | ART      | No ART      | 2.82 (1.98–4.03) | 9.33 (4.22–20.62) |
| Epelboin S [48] a | 2021 | ART_end  | SC_end      | 2.94 (2.55–3.38) | 2.43 (2.10–2.82) |
| Cochrane E [49] | 2020 | ART      | SC          | 10.39 (1.20–89.97) | –            |
| Salmanian B [51] | 2020 | ART      | No ART      | 2.41 (1.27–4.55) | –            |
| Shinohara S [52] | 2020 | ART      | SC          | 0.66 (0.19–2.26) | –            |
| Farella M [53] a | 2020 | ART_end  | SC_end      | 6.09 (1.25–29.60) | –            |
| Petersen SH [54] | 2020 | ART      | SC          | 5.27 (5.06–5.49) | 3.87 (3.70–4.04) |
| Tanaka H [55]   | 2020 | ART      | No ART      | 2.76 (1.85–4.10) | 1.95 (1.24–3.06) |
| Miura M [26]    | 2019 | ART      | No ART      | 2.55 (1.67–3.89) | 2.71 (1.70–4.31) |
| Santi E [57]    | 2019 | ART      | No ART      | 5.56 (2.74–11.25) | –            |
| Szymusik I [60] | 2019 | ART      | SC          | 5.18 (1.14–23.55) | –            |
| Yang P [61]     | 2019 | ART      | No ART      | 1.57 (1.29–1.91) | –            |
| Nagata C [88]   | 2019 | ART      | SC          | 3.94 (3.04–5.11) | 2.45 (1.87–3.20) b |
| Rahu K [62]     | 2019 | ART      | SC          | 8.23 (4.98–13.60) | –            |
| Sabban H [65]   | 2017 | ART      | No ART      | 6.28 (5.45–7.24) | 3.14 (2.71–3.64) |
| Li H [66] a     | 2017 | ART_end  | No ART_end  | 16.56 (0.77–357.62) | –            |
| Qin J [67]      | 2017 | ART      | No ART      | 2.73 (1.77–4.20) | 4.11 (2.12–7.96) |
| Zhu L [69]      | 2016 | ART      | SC          | 2.15 (1.74–2.65) | 2.23 (1.79–2.78) |
| Ginström E [72] | 2016 | ART      | SC          | 6.13 (5.59–6.72) | 6.38 (5.31–7.66) c |
| Valenzuela B [73] | 2016 | ART      | No ART      | 1.96 (0.47–8.28) | –            |
| Yang X [78]     | 2014 | ART      | SC          | 4.46 (3.32–5.99) | 2.18 (1.62–2.94) |
| Raisänen S [79] | 2013 | ART      | No ART      | 8.17 (6.54–10.21) | –            |
| Hayashi M [82]  | 2012 | ART      | SC          | 2.15 (1.65–2.81) | 2.2 (1.68–2.87) |
| Healy DL [85]   | 2010 | ART      | No ART      | 2.37 (1.95–2.87) | 2.34 (1.87–2.92) |
| Verlaenen H [86] | 1995 | ART      | No ART      | 9.26 (0.49–173.70) | –            |
| Hill GA [87]    | 1990 | ART      | No ART      | 4.18 (0.74–23.47) | –            |

a All cases were women with endometriosis. b Data (OR for ART and intracytoplasmic sperm injection) were combined by the author. c: women with cleavage stage were excluded. Some values listed might be slightly different from the original values because the calculation was performed using RevMan version 5.4.1 or they were estimated by the authors. Abbreviations: OR, odds ratio; cOR, crude odds ratio; aOR, adjusted odds ratio; Exp, experimental group; Control, control group; ART, assisted reproductive technology; SC, spontaneous conception; CI, confidence interval; –, not applicable; ART_end; women with endometriosis conceived by ART; SC_end; spontaneous conception with endometriosis.
Figure 3. Effect of assisted reproductive technology on the prevalence of placenta previa. The pooled odds ratios (ORs) for the (A) unadjusted analysis of placenta accreta spectrum disorder (PASD) and (B) adjusted analysis of placenta previa for women who conceived using ART and women who conceived without ART. Forest plots were ordered within the stratum by relative weight (%) and the publication year of the study. Considerable heterogeneity was observed during the unadjusted analysis (A: $I^2 = 99\%$) and during the adjusted analysis (B: $I^2 = 92\%$). Some values might be slightly different from the original values, because the calculations were performed using RevMan ver. 5.4.1. Abbreviations: ART, assisted reproductive technology; PP, placenta previa; OR, odds ratio; CI, confidence interval; SE, standard error.
3.5. Primary Outcome: Association between ART and Placenta Previa (Sensitivity Analysis)

To enhance the robustness of the results that showed a positive association between ART and placenta previa, we conducted a sensitivity analysis comparing the following groups: (i) ART with endometriosis and ART without endometriosis; (ii) women with endometriosis who conceived using ART and women with endometriosis who conceived spontaneously; (iii) those who used frozen ET and those who used fresh ET; and (iv) the hormone replacement cycle (HRC) and the normal cycle (NC). Among these analyses, we considered that the comparison of women with endometriosis who used ART and women without endometriosis who used ART was essential to evaluating the effect of ART on women with endometriosis.

3.5.1. Effect of Endometriosis on the Prevalence of Placenta Previa for Women Who Conceived Using ART

Seven retrospective studies were included to determine the effect of endometriosis on the prevalence of placenta previa by comparing women with endometriosis who conceived using ART \((n = 1914)\) and women without endometriosis who conceived using ART \((n = 7917)\) (Table 4) \([47,68,70,71,81,83,85]\). According to the unadjusted random-effects analysis, endometriosis was associated with a higher rate of placenta previa (Figure 4A) \((n = 7; \text{OR} \ 4.09, 95\%CI 1.93–8.69; \text{heterogeneity: } p < 0.01, I^2 = 73\%)\). These results suggest that endometriosis has an additive effect that increased the rates of placenta previa for women who conceived using ART.

Table 4. Rates of placenta previa for women who conceived using ART (sensitivity analysis).

| Author         | Year | No. Exp | No. Control | Exp End (%) | cOR   | aOR   |
|----------------|------|---------|-------------|-------------|-------|-------|
| **Endometriosis versus Non-endometriosis (women with ART)** |      |         |             |             |       |       |
| Wang J [47]  | 2021 | 74      | 1167        | 74/1167 (6.0\%) | 3.51  | 1.57–7.80 |
| Fujii T [68] | 2016 | 92      | 512         | 92/604 (15.2\%) | 12.10 | 3.56–41.06 |
| Benaglia L [70]| 2016 | 239     | 239         | –           | 4.89  | 1.39–17.26 |
| Jacques M [71]| 2016 | 113     | 113         | 160/2315 (6.9\%) | 1.00  | 0.20–5.06  |
| Takeamura Y [81]| 2013 | 53     | 265         | 53/318 (16.7\%) | 6.20  | 0.63–60.61 |
| Benaglia L [83]| 2012 | 78     | 156         | –           | 13.55 | 3.94–45.22 |
| Healy DL [85]| 2010 | 1265    | 5465        | 1265/6730 (18.8\%) | 1.67  | 1.19–2.34 |
| **ART versus SC (in women with endometriosis)** |      |         |             |             |       |       |
| Epelboin S [48]| 2021 | 6934 | 31,101      | 6934/38,035(18.2\%) | 2.94  | 2.55–3.38 |
| **ART with endometriosis versus SC without endometriosis** |      |         |             |             |       |       |
| Epelboin S [48]| 2021 | 6934 | 4,083,732   | –           | 8.82  | 7.89–9.86 |
| **Frozen ET versus Fresh ET** |      |         |             |             |       |       |
| Zargar M [44]| 2021 | 356     | 313         | –           | 0.93  | 0.46–1.87 |
| Shinohara S [52]| 2020 | 330     | 112         | –           | 0.68  | 0.06–7.54 |
| Sakai Y [58]| 2019 | 60      | 27          | –           | 1.41  | 0.35–5.69 |
| Ginström E [72]| 2016 | 7795    | 22,771      | –           | 0.51  | 0.40–0.65 |
| Takeshima K [74]| 2016 | 90,783 | 50,445      | –           | 0.79  | 0.70–0.89 |
| Kaser DJ [75]| 2015 | 42      | 157         | –           | 0.81  | 0.33–2.00 |
| Rombauts L [76]| 2014 | 1586    | 2951        | 99/1586 (6.2\%) | 0.54  | 0.36–0.80 |
| Koresec S [77]| 2014 | 211     | 915         | 43/211 (20.4\%) | 0.06  | 0.00–1.05 |
| Liu SY [80]| 2013 | 1531a  | 1914a       | –           | 1.46  | 0.49–4.36 |
| Healy DL [85]| 2010 | 2045    | 4058        | –           | 0.82  | 0.59–1.14 | 1.37 (0.96–1.95) \(^c\)
### Table 4. Cont.

| Author            | Year | No. Exp | No. Control | Exp End (%) | cOR  | aOR  |
|-------------------|------|---------|-------------|-------------|------|------|
| Hu KL [45]        | 2021 | 2561    | 3790        | 122 (4.8%)  | 0.58 | (0.27–1.24)  |
| Asserhøj LL [46]  | 2021 | 357     | 731         | 16 (5.0%)   | 1.10 | (0.46–2.62)  |
| Saito K [59]      | 2019 | 24,225  | 10,755      | --          | 0.80 | (0.59–1.08)  |
| Rombauts L [76]   | 2014 | 355     | 1231        | --          | 2.02 | (0.98–4.14)  |

* HRC versus NC (Frozen ET)

---

* Day 3 embryo.  
Two cases involved frozen embryo transfer.  
Calculated by the author. Some values listed might be slightly different from the original values because the calculation was performed using Revman ver. 5.4.1 or they were estimated by the authors. Abbreviations: Exp, Experimental; End, endometriosis; Exp End, the rate of endometriosis in the experimental group; ART, assisted reproductive technology; --, not applicable; Frozen, frozen embryo transfer; Fresh, fresh embryo transfer; ET, embryo transfer; No., number; OR, odds rate; cOR, crude odds ratio; aOR, adjusted odds ratio; No. Exp: number of women included in the experimental group; No. Control, number of women included in the control group; ART_non-end, women without endometriosis conceived by ART; SC_end, spontaneous conception with endometriosis; SC_non-end, spontaneous conception without endometriosis; HRC, hormone replacement cycle; NC, natural cycle.

---

**Figure 4. Cont.**

[A] B C
During our previous systematic review, we examined the effect of ART on the incidence of PASD [15]. However, because we did not collect data regarding endometriosis or examine the influence of endometriosis on the rate of PASD during our previous study or examine the influence of endometriosis on the rate of PASD during our previous study, we conducted an unadjusted random-effects analysis. Women who conceived using ART were less likely to have placenta previa than those who conceived spontaneously (Figure 4B) \( (n = 1: \text{OR } 0.71, 95\% \text{CI } 0.57–0.88; \text{heterogeneity: } p = 0.03, I^2 = 52\%) \) than women who conceived using fresh ET.

For a more in-depth examination of the effect of ART, a sensitivity analysis was conducted according to the type of ART (Table 4 and Supplemental Table S3; fresh ET versus frozen ET). During this analysis, 10 studies investigating 104,739 pregnancies conceived using frozen ET and 83,663 pregnancies conceived using fresh ET were identified [44, 52, 58, 72, 74–77, 80, 85]. For this analysis, an unadjusted random-effects analysis was conducted. Women who conceived using ART were more likely to have placenta previa than those who conceived spontaneously (Figure 4B) \( (n = 1: \text{OR } 2.94, 95\% \text{CI } 2.55–3.38) \). Although this result was based on only one study, it is possible that ART has an additive effect that increased the frequency of placenta previa for women with endometriosis.

Four studies determined and compared the rates of placenta previa for women who conceived using frozen ET with the HRC and for women who conceived using frozen ET with the NC. This comparison showed a similar rate of placenta previa (Figure 4D) \( (n = 4: \text{OR } 1.14, 95\% \text{CI } 0.72–1.80; \text{heterogeneity: } p = 0.02, I^2 = 54\%) \) for the two groups.
the influence of endometriosis on the rate of PASD during our previous study [15], we performed a meta-analysis by revising the keywords for the literature search to include women with endometriosis, updating the study period, and correcting the data regarding endometriosis.

Of the included studies, only two clarified the rate of endometriosis. These limited data are inadequate for determining the effect of endometriosis on women who used ART (Supplemental Table S4). As shown in Table 5, 15 studies (4 of low and 11 of moderate quality) examined the effect of ART on the incidence of PASD for pregnant women [43,47,49–51,55,56,59,69,82,84]. Of those 15 studies, 10 compared the PASD rates of women who used ART and those of women who did not use ART, and five determined the prevalence of PASD according to the type of ART (four compared frozen ET and fresh ET and one compared HRC and NC).

### Table 5. Effect of ART on PASD rates.

| Author          | Year | Exp       | Control | No. Exp | No. Control | cOR   | aOR   |
|-----------------|------|-----------|---------|---------|-------------|-------|-------|
| Wang Y [43]     | 2021 | ART       | No ART  | 269,738 | 16,609,990  | 2.46 (2.42–2.51) | –     |
| Wang J [47]     | 2021 | ART       | No ART  | 1241    | 6832        | 1.66 (1.18–2.34) | 1.67 (1.16–2.41) * |
| Cochrane E [49] | 2020 | ART       | SC      | 120     | 240         | 14.33 (7.73–279.66) | –     |
| Modest AM [50]  | 2020 | ART       | No ART  | 1418    | 26,926      | 7.41 (4.88–11.24) | –     |
| Salmanian B [51]| 2020 | ART       | No ART  | 571     | 36,890      | 3.61 (2.01–6.50) | –     |
| Tanaka H [55]   | 2020 | ART       | No ART  | 811     | 6141        | 7.72 (4.00–14.90) | 7.35 (3.20–16.6)   |
| Kyozuka H [56]  | 2019 | ART       | No ART  | 2658    | 87,896      | 8.02 (5.64–11.39) | 6.78 (4.54–10.14) |
| Zhu L [69]      | 2016 | ART       | SC      | 2641    | 5282        | 2.38 (1.93–2.94) | 2.37 (1.90–2.95)   |
| Hayashi M [82]  | 2012 | ART       | SC      | 4570    | 4264        | 2.67 (1.42–5.03) | –     |
| Esh-Broder E [84]| 2011| ART       | SC      | 752     | 24,441      | 13.20 (6.73–25.88) | –     |

*Calculated by the author.

**Frozen ET versus Fresh ET**

| Author          | Year | Exp       | Control | No. Exp | No. Control | cOR   | aOR   |
|-----------------|------|-----------|---------|---------|-------------|-------|-------|
| Sakai Y [58]    | 2019 | Frozen    | Fresh   | 60      | 27 b       | 5.79 (1.24–27.01) | –     |
| Takeshima K [74]| 2016 | Frozen    | Fresh   | 90,783  | 50,445      | 5.11 (3.60–7.25) | –     |
| Kaser DJ [75]   | 2015 | Frozen    | Fresh   | 42      | 157         | 2.23 (1.07–4.62) | 3.20 (1.14–9.02) |
| Korosec S [77]  | 2014 | Frozen    | Fresh   | 211     | 915         | 1.05 (0.45–2.43) | –     |

**HRC versus NC (Frozen ET)**

| Author          | Year | Exp | Control | No. Exp | No. Control | cOR   | aOR   |
|-----------------|------|-----|---------|---------|-------------|-------|-------|
| Saito K [59]    | 2019 | HRC | NC      | 24,225  | 10,755      | 5.76 (3.12–10.64) | 6.91 (2.87–16.66) |

Updated and modified from Sci Rep. 2021;11:920 Matsuzaki S et al. Antenatal diagnosis of placenta accreta spectrum after in vitro fertilization –embryo transfer: a systematic review and meta-analysis/Supplemental Table S2, Meta-table of the included studies [15]. *Calculated by the author. b Two cases involved frozen embryo transfer. Some values listed might be slightly different from the original values because the calculation was performed using Revman ver. 5.4.1. Some values listed might be slightly different from the original values, because they were estimated by the authors. Abbreviations: Exp, Experimental; End, endometriosis; PASD, placenta accreta spectrum; ART, assisted reproductive technology; SC, spontaneous conception; –, not applicable; Frozen, frozen embryo transfer; Fresh, fresh embryo transfer; ET, embryo transfer; No., number; No. Exp, number of women in the experimental group; No. Control, number of women in the control group; HRC, hormone replacement cycle; NC, natural cycle; OR, odds ratio; cOR, crude odds ratio; aOR, adjusted odds ratio.

### 3.6.1. ART-Conceived Pregnancy versus Pregnancy Conceived without ART

Using the 10 studies that compared ART-conceived pregnancy (n = 284,520) and pregnancy without the use of ART (n = 16,808,902), we performed an unadjusted random-effects analysis to examine the effect of ART on the prevalence of PASD (Figure 5A). According to those 10 studies, ART-conceived pregnancy was associated with an increased rate of PASD (n = 10: OR 4.22, 95%CI 2.95–6.03; heterogeneity: p < 0.01, I² = 92%). The results of the adjusted random-effects analysis were similar to those of the unadjusted analysis (Figure 5B) (n = 4: OR 3.54, 95%CI 1.86–6.76; heterogeneity: p < 0.01, I² = 91%).
Figure 5. Effect of assisted reproductive technology on the incidence of placenta accreta spectrum. The pooled odds ratios (ORs) for the (A) unadjusted analysis of PASD and (B) adjusted analysis of PASD for women who conceived using ART and women who conceived without ART. Forest plots were ordered within the stratum by relative weight (%) and the publication year of the study. Considerable heterogeneity was observed during the unadjusted analysis (A: $I^2 = 92\%$) and the adjusted analysis (B: $I^2 = 91\%$). Some values might be slightly different from the original values, as calculations were performed using RevMan ver. 5.4.1. Abbreviations: ART, assisted reproductive technology; OR, odds ratio; CI, confidence interval; SE, standard error; PASD, placenta accreta spectrum disorder.

3.6.2. Sensitivity Analysis of Frozen ET versus Fresh ET and of HRC versus NC

During the sensitivity analyses, the effect of ART on the PASD rates was examined according to the ART type. The comparison of frozen ET and fresh ET showed that frozen ET was associated with a higher incidence of PASD (Figure 6A) ($n = 4$: OR 2.79, 95%CI, 1.22–6.37; heterogeneity: $p < 0.01$, $I^2 = 79\%$).
Figure 6. Effect of assisted reproductive technology on the incidence of placenta accreta spectrum (sensitivity analysis). The pooled odds ratios (ORs) for the unadjusted analysis of (A) comparisons between frozen embryo transfer (ET) and fresh ET and of (B) comparisons between the hormone replacement cycle (HRC) and normal cycle (NC) in one study. Forest plots were ordered within the stratum by relative weight (%) and the publication year of the study. Considerable heterogeneity was observed during both unadjusted analyses (A: $I^2 = 79\%$). Some values might be slightly different from the original values, as calculations were performed using RevMan ver. 5.4.1. Abbreviations: ART, assisted reproductive technology; OR, odds ratio; CI, confidence interval; SE, standard error; PASD, placenta accreta spectrum.

The comparison of the HRC and NC showed that HRC was associated with an increased rate of PASD (Figure 6B) ($n = 1$: OR 5.76, 95%CI, 3.12–10.64). These results suggest that frozen ET with the HRC may be the most significant type of ART that is associated with higher rates of PASD.

3.7. Secondary Outcomes: Effect of Endometriosis on the Diagnosis of PASD

3.7.1. Systematic Review Results

We performed a systematic literature search to find a study that examined the effect of endometriosis on the diagnosis of PASD. However, we could not find any study that has examined the effect of endometriosis on the accuracy of the PASD diagnosis.

3.7.2. Narrative Review of the Diagnosis of PASD for Women with Endometriosis

To date, the effect of endometriosis on the PASD diagnosis remains unclear. Since approximately 20% to 30% of women with endometriosis conceived using ART, we reviewed the effect of ART on the accuracy of the PASD diagnosis. According to a retrospective study performed in Japan, the diagnostic accuracy for PASD after ART with placenta previa was examined using magnetic resonance imaging (MRI) [19]. During this study, the antenatal diagnosis rate using MRI for women with PASD who conceived using ART was significantly lower than that for women with PASD who conceived without ART ($2/9$ [22.2%] versus $18/19$ [94.7%]; $p < 0.01$) [19].
Another study performed in the United States that investigated the antenatal diagnosis rate of PASD using ultrasonography [50] showed that the antenatal diagnosis of PASD after ART was significantly lower than that for women with PASD who conceived without ART (<4/31 [<12.9%] versus 38/81 [46.9%]; \( p < 0.01 \)) [50]. These results suggest that ART-induced PASD has the potential to be associated with lower diagnostic accuracy compared to PASD without ART.

4. Discussion

4.1. Principal Findings

This study resulted in four principal findings. First, endometriosis is associated with an increased incidence of PASD; Second, ART, especially fresh ET, is associated with an increased rate of placenta previa; Third, ART, especially frozen ET during the HRC, is associated with a higher prevalence of PASD; Fourth, the surgical outcomes of cesarean hysterectomy for women with PASD and endometriosis have not been reported. Although the relationship between endometriosis and the increased incidence of PASD is unique, the mechanism of the increased rate of PASD is unresolved, and a meta-analysis evaluating the effect of endometriosis and excluding confounding risk factors for PASD (advanced maternal age, increased rate of ART, increased rate of placenta previa) was impossible. Therefore, future studies are warranted.

4.2. Strengths and Limitations

This study is likely the first to focus on the effect of endometriosis on the prevalence of PASD. This study revealed that endometriosis is correlated with a higher incidence of PASD. We evaluated the association between ART and placenta previa as well as the association between ART and PASD. Because approximately 20% to 30% of women with endometriosis conceive using ART, these investigations are useful for clinicians. Notably, no meta-analysis of the effect of ART on the frequency rates of placenta previa and PASD and no sensitivity analysis of endometriosis have been reported previously. Therefore, our results may be useful for clinicians.

This study had several notable limitations. First, because all eligible studies were retrospective, unmeasured bias may exist. Other possible confounding factors in the eligible studies were the definitions of endometriosis that varied among studies, the limited number of studies that examined the association between endometriosis and PASD, the fact that most meta-analyses had considerable heterogeneity among the studies, and the low quality of the diagnoses of PASD and endometriosis in some of the studies. These factors may have created severe bias in the study and in the considerable heterogeneity among the studies.

Second, although the surgical outcomes of women with PASD complicated with endometriosis during cesarean hysterectomy are essential to the impact of endometriosis on the rate of PASD, this information was lacking due to the absence of previous studies. Future studies that examine the surgical outcomes of PASD complicated with endometriosis are warranted. Third, because no studies have examined the effect of endometriosis on the rate of PASD according to the severity of endometriosis, the association between severe endometriosis and PASD and the association between non-severe endometriosis and PASD are still unclear. Further studies are necessary to identify these associations.

Fourth, we could not examine the effect of endometriosis on the incidence of PASD after excluding confounding factors. Because women with endometriosis are more likely to use ART to conceive, more likely to be of advanced maternal age, and more likely to have placenta previa compared to those without endometriosis [14,96], it is essential to exclude the cofounding factors. However, none of the studies performed a multivariate analysis with adjustments for the obstetric background; therefore, our analysis cannot characterize endometriosis as a risk factor for PASD after excluding the confounding factors [27,47,63,64].

Finally, during the analysis of ART and PASD, although various obstetric factors (advanced maternal age, placenta previa, prior uterine surgery, etc.) are associated with
an increased rate of PASD, none of the studies performed a multivariate analysis with adjustments for these obstetric factors; therefore, our analysis cannot illustrate ART as a risk factor for PASD after excluding the confounding factors [43,47,49–51,55,56,59,69,82,84]. These are notable limitations that others should be aware of when interpreting the results of this study.

4.3. Comparisons with the Existing Literature

The association between endometriosis and an increased risk of placenta previa is robust [23,24,29,97,98]. Notably, placenta previa is the most significant risk factor for PASD [15,17,98–101]. Although our study identified that endometriosis is a risk factor for PASD, no studies have examined the influence of endometriosis on the rate of PASD after excluding the effect of the increased rate of placenta previa. Further studies that adjust for the effect of the confounding factors for PASD (placenta previa, ART-conceived pregnancy, prior uterine surgery, etc.) are warranted to examine the association between endometriosis and PASD.

4.3.1. Association between Endometriosis and ART

Endometriosis has been reported to affect approximately 10% to 15% of women of reproductive age [102]. According to our included studies, the rate of ART-conceived pregnancy for women with endometriosis ranged from 18.2% to 37.2% [26,53,66]. These rates are similar to those reported by previous studies (11.9–26.0%) [103–105]. Although the definition of endometriosis is different among studies, approximately one-fourth of women with endometriosis conceive using ART [26,53,66,102–105]. Therefore, we consider the relationship between ART and placenta previa, as well as that between ART and PASD, essential to examining the influence of ART on the frequency of PASD.

4.3.2. Association between ART and Placenta Previa

Some systematic reviews have examined the association between ART and placenta previa. ART-conceived pregnancy was associated with an increased rate of placenta previa compared to pregnancies conceived without ART [97,106]. Although the rate of placenta previa was similar for frozen ET and fresh ET (OR 0.70, 95%CI, 0.46–1.08) according to a previous systematic review in 2018, our study showed that frozen ET is associated with a decreased rate of placenta previa (OR 0.71, 95%CI, 0.57–0.88) compared to fresh ET [97]. Since our systematic review is the latest review of this topic, the inconsistency in the results may be attributable to the difference in the number of included studies.

A previous retrospective study that determined an association between endometrial thickness and placenta previa found that women with endometrial thickness more than 12 mm were more likely to have placenta previa (adjusted OR 3.74, 95%CI, 1.90–7.34) than women with endometrial thickness less than 9 mm [76]. Previous studies have reported that the endometrial thickness was thinner in women who conceived with frozen ET than in women who conceived with fresh ET [76,107,108]. Therefore, a possible mechanism for the decreased rate of placenta previa for women who conceived using frozen ET is the thinner endometrial thickness.

4.3.3. Association between ART and PASD

During our previous systematic review, we examined the effect of ART-conceived pregnancy on the prevalence of PASD compared with the effect of pregnancy conceived without ART [15]. During this updated systematic review, we attempted to examine the effect of endometriosis on the incidence of PASD for women with ART, which was impossible due to the lack of studies. Although we added three new studies to this analysis, the results were similar to those of our previous study [15]. Further studies are necessary to examine the effect of endometriosis on the prevalence of PASD with ART-conceived pregnancy.
4.3.4. Possible Mechanism of the Increased Rate of PASD for Women with Endometriosis

As shown in Figure 7, the results of our study revealed a possible mechanism for the increased rate of PASD for women with endometriosis. We believe that the risk of PASD may be high for placenta previa patients with endometriosis who conceived using frozen ET.

![Figure 7](image)

**Figure 7.** Our hypothesis of the possible mechanism of the increased rate of placenta accreta spectrum disorder. The red arrow indicates the effect of endometriosis on the increased rate of PASD. The light blue arrow indicates the effect of assisted reproductive technology (ART) on the increased rate of PASD. (A) For women with endometriosis who conceived without ART, endometriosis itself may be associated with an increased rate of PASD. Because endometriosis is associated with an increased rate of placenta previa, this may indirectly contribute to a higher rate of PASD. (B) For women with endometriosis who conceived using ART, ART may have an additive effect that increased the rate of placenta previa and PASD. As a result, we believe that women with endometriosis who conceived using ART are at a high risk for PASD. Abbreviations: PP, placenta previa; PASD, placenta accreta spectrum disorder; ART, assisted reproductive technology.

4.3.5. Proposed Antenatal Management of PASD and Endometriosis

A prenatal diagnosis of PASD contributes to the reduction of hemorrhagic complications and improvements in the surgical outcomes of PASD, possibly due to the comprehensive multidisciplinary intraoperative treatment, including planned cesarean hysterectomy, transfusion preparation, and treatment administered by skilled surgeons, available for these women [22,109–111]. Previous studies suggested that the prenatal diagnosis rate of PASD are low for women with PASD who conceived using ART [19,50]. Therefore, clinicians should focus on the presence of PASD in women with endometriosis using ART who have risk factors for PASD (e.g., placenta previa, prior uterine surgery, advanced maternal age, etc.).

Our previous retrospective study reported that MRI can predict posterior uterine adhesions in patients with placenta previa. During this study, 96 patients with placenta previa were included; 21 of those patients had posterior uterine adhesions, probably because of endometriosis [22]. Nevertheless, we focused on the angle of the uterine cervix during the study and found that women with a retroverted cervix were more likely to have uterine posterior adhesions than women with an anteverted cervix (60% versus 8.5%; \( p < 0.01 \)) [23]. Although the cost of MRI is high in developed countries, it has the potential to detect the presence of endometriosis in women with placenta previa [112].

4.3.6. Proposed Intraoperative Management of PASD and Endometriosis

Cesarean hysterectomy for women with PASD is widely performed; however, its surgical outcomes for women with endometriosis have not been thoroughly determined.
No studies have proposed an intraoperative surgical technique for PASD patients with endometriosis; therefore, morbidity during cesarean hysterectomy may be high.

Cesarean hysterectomy without placental removal is the standard treatment for women with PASD. Nevertheless, “conservative management” is an option that aims to decrease maternal morbidity for women with PASD [1,113,114]. A retrospective, multicenter study of 167 women with PASD who received conservative management showed that only 42% received transfusions and 78% avoided hysterectomy [113]. Although 6% of women had severe maternal morbidity, such as delayed infection and hemorrhage, these results were considered important to the treatment of PASD.

Moreover, a recent multicenter, prospective study (the PACCRETA prospective study) showed that conservative management of PASD is associated with a lower risk of transfusion (>4 units of red blood cells) within 6 months compared to cesarean hysterectomy [115]. Because the surgical morbidity of PASD patients with endometriosis may be high, we believe that this approach has the potential to improve surgical outcomes.

5. Conclusions and Implications
5.1. Implications for Practice
Endometriosis may correlate with unfavorable surgical outcomes, such as massive hemorrhage, bladder injury, and rectal injury, in cesarean hysterectomy. Moreover, an increased incidence of PASD was found in women with endometriosis compared with those without endometriosis. Thus, future research focusing on the surgical morbidity of pregnant women with PASD and endometriosis is necessary. Furthermore, it remains essential to identify intraoperative treatments or surgical techniques that could improve the surgical morbidity of pregnant women with PASD complicated with endometriosis.

5.2. Implications for Clinical Research
Although the diagnosis of endometriosis during pregnancy is essential, there is a paucity of studies evaluating the diagnostic techniques applied in pregnant women. Since MRI is costly and not suitable for screening, future studies evaluating the usefulness of diagnosing endometriosis during pregnancy applying transvaginal ultrasonography are warranted.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/biomedicines10020390/s1, Supplemental Figure S1. Intraoperative image of placenta accreta spectrum complicated with cesarean hysterectomy; Supplemental File S1. The search strategy; Supplemental Table S1. Meta data of included studies; Supplemental Table S2. Metadata of studies (the rate of placenta previa: ART versus No ART and SC); Supplemental Table S3. Metadata of studies (the effect of ART on the rate of placenta previa: sensitivity analysis); Supplemental Table S4. Metadata of studies (the effect of ART on the rate of placenta accreta spectrum disorder); Supplemental Table S5. Risk of bias assessment for the comparator study.

Author Contributions: S.M. (Shinya Matsuzaki), Y.N., M.K., S.K. (Sahori Kakuda), H.S., T.H. and Y.U. designed the study, initiated the collaborations, cleaned and analyzed the data, created the figures and tables, interpreted the results, and drafted and revised the manuscript with others. S.M. (Shinya Matsuzaki) is the corresponding author of the study. S.M. (Satoko Matsuzaki) contributed to the literature overview, intellectual inputs, interpreted the results and edited the manuscript. M.K., S.M. (Satoko Matsuzaki) and S.M. (Shinya Matsuzaki) contributed to the study concept and design, instructed on the analytic approach, and interpreted the results. S.K. (Shoji Kamiura) supervised the study and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The approval of the Institutional Review Board was exempted due to the use of publicly available data.

Informed Consent Statement: Not applicable.
**Data Availability Statement:** All the studies used in this study are published in the literature.

**Conflicts of Interest:** Research funding, MSD (Sh.M.); none for others. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**References**

1. Matsuzaki, S.; Yoshino, K.; Endo, M.; Kakigano, A.; Takiuchi, T.; Kimura, T. Conservative management of placenta percreta. *Int. J. Gynecol. Obstet.* 2018, 140, 299–306. [CrossRef] [PubMed]
2. Cahill, A.G.; Beigi, R.; Heine, R.P.; Silver, R.M.; Wax, J.R. Placenta Accreta Spectrum. *Am. J. Obstet. Gynecol.* 2018, 219, B2–B16. [CrossRef]
3. Senthilnes, L.; Goffinet, F.; Kayem, G. Management of placenta accreta. *Acta Obstet. Gynecol. Scand.* 2013, 92, 1125–1134. [CrossRef]
4. Licon, E.; Matsuzaki, S.; Opara, K.N.; Ng, A.J.; Bender, N.M.; Grubbs, B.H.; Lee, R.H.; Ouzounian, J.G.; Pham, H.Q.; Brunette, L.L.; et al. Implementation of multidisciplinary practice change to improve outcomes for women with placenta accreta spectrum. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2020, 246, 194–196. [CrossRef] [PubMed]
5. Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. *Obstet. Gynecol.* 2018, 132, e259–e275. [CrossRef]
6. Jauniaux, E.; Alfavrevic, Z.; Bhide, A.G.; Belfort, M.; Burton, G.J.; Collins, S.; Dorman, S.; Jurkovic, D.; Kayem, G.; Kingdom, J.; et al. Placenta Praevia and Placenta Accreta: Diagnosis and Management. *BJOG* 2019, 126, e1–e48. [CrossRef] [PubMed]
7. O’Brien, J.M.; Barton, J.R.; Donaldson, E.S. The management of placenta percreta: Conservative and operative strategies. *Am. J. Obstet. Gynecol.* 1996, 175, 1632–1638. [CrossRef]
8. Laganà, A.S.; Garzon, S.; Götte, M.; Viganò, P.; Franchi, M.; Ghezzi, F.; Martin, D.C. The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights. *Int. J. Mol. Sci.* 2019, 20, 5615. [CrossRef]
9. Lin, Y.H.; Chen, Y.H.; Chang, H.Y.; Au, H.K.; Tseng, C.R.; Huang, Y.H. Chronic Niche Inflammation in Endometriosis-Associated Infertility: Current Understanding and Future Therapeutic Strategies. *Int. J. Mol. Sci.* 2018, 19, 2385. [CrossRef]
10. Fuldeore, M.J.; Soliman, A.M. Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women. *Gynecol. Obstet. Investig.* 2017, 82, 453–461. [CrossRef]
11. Macer, M.L.; Taylor, H.S. Endometriosis and infertility: A review of the pathogenesis and treatment of endometriosis-associated infertility. *Obstet. Gynecol. Clin. N. Am.* 2012, 39, 535–549. [CrossRef]
12. Meuleman, C.; Vandenabeele, B.; Fieuws, S.; Spiessens, C.; Timmerman, D.; D’Hooghe, T. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. *Fertil. Steril.* 2009, 92, 68–74. [CrossRef] [PubMed]
13. Horton, J.; Sterrenburg, M.; Lane, S.; Maheshwari, A.; Li, T.C.; Cheong, Y. Reproductive, obstetric, and perinatal outcomes of women with adenomyosis and endometriosis: A systematic review and meta-analysis. *Hum. Reprod. Updat.* 2019, 25, 593–633. [CrossRef] [PubMed]
14. Senapati, S.; Sammel, M.D.; Morse, C.; Barnhart, K.T. Impact of endometriosis on in vitro fertilization outcomes: An evaluation of the Society for Assisted Reproductive Technologies Database. *Fertil. Steril.* 2016, 106, 164–171.e1. [CrossRef] [PubMed]
15. Matsuzaki, S.; Nagase, Y.; Takiuchi, T.; Kakigano, A.; Mimura, K.; Lee, M.; Matsuzaki, S.; Ueda, Y.; Tomimatsu, T.; Endo, M.; et al. Antenatal diagnosis of placenta accreta spectrum after in vitro fertilization-embryo transfer: A systematic review and meta-analysis. *Sci. Rep.* 2021, 11, 9205. [CrossRef] [PubMed]
16. Rosenberg, T.; Pariente, G.; Sergienko, R.; Wizinower, A.; Sheiner, E. Critical analysis of risk factors and outcome of placenta previa. *Arch. Gynecol. Obstet.* 2011, 284, 47–51. [CrossRef] [PubMed]
17. Matsuzaki, S.; Manivelbaum, R.S.; Sangara, R.N.; McCarthy, L.; Vestal, N.L.; Klar, M.; Matsushima, K.; Amaya, R.; Ouzounian, J.G.; Matsuo, K. Trends, characteristics, and outcomes of placenta accreta spectrum: A national study in the United States. *Am. J. Obstet. Gynecol.* 2021, 225, 534.e1–534.e38. [CrossRef] [PubMed]
18. Eisenberg, V.H.; Weil, C.; Chodick, G.; Shalev, V. Epidemiology of endometriosis: A large population-based database study from a healthcare provider with 2 million members. *BJOG* 2018, 125, 55–62. [CrossRef]
19. Nagase, Y.; Matsuzaki, S.; Mizuta-Odani, C.; Onishi, H.; Tanaka, H.; Nakagawa, S. In-vitro fertilisation-embryo-transfer complicates the antenatal diagnosis of placenta accreta spectrum using MRI: A retrospective analysis. *Clin. Radiol.* 2020, 75, 927–933. [CrossRef]
20. Uccella, S.; Marconi, N.; Casarin, J.; Cecconari, M.; Boni, L.; Sturla, D. Impact of endometriosis on surgical outcomes and com-plications of total laparoscopic hysterectomy. *Arch. Gynecol. Obstet.* 2016, 294, 771–778. [CrossRef]
21. Hwang, J.H.; Lim, M.C.; Joun, J.Y.; Seo, S.S.; Kang, S.; Seo, H.K.; Chung, J.; Park, S.-Y. Urologic complications of laparoscopic radical hysterectomy and lymphadenectomy. *Int. Urogynecol. J.* 2012, 23, 1605–1611. [CrossRef] [PubMed]
22. Matsuzaki, S.; Okada, A.; Endo, M.; Nagase, Y.; Nakagawa, S.; Hiramatsu, K.; Kakigano, A.; Mimura, K.; Takiuchi, T.; Tomimatsu, T.; et al. Horizontal Cervix as a Novel Sign for Predicting Adhesions on the Posterior Extrauterine Wall in Cases of Placenta Previa. *J. Clin. Med.* 2019, 8, 2141. [CrossRef] [PubMed]
23. Lalani, S.; Choudhry, A.J.; Firth, B.; Bacal, V.; Walker, M.; Wen, S.W.; Singh, S.; Amath, A.; Hodge, M.; Chen, I. Endometriosis and adverse maternal, fetal and neonatal outcomes, a systematic review and meta-analysis. *Hum. Reprod.* 2018, 33, 1854–1865. [CrossRef]
24. Zullo, F.; Spagnolo, E.; Saccone, G.; Acunzo, M.; Xodo, S.; Cecconari, M.; Berghella, V. Endometriosis and obstetrics complications: A systematic review and meta-analysis. Fertil. Steril. 2017, 108, 667–672.e5. [CrossRef]

25. Uccella, S.; Manzoni, P.; Cromi, A.; Marconi, N.; Gisone, B.; Miraglia, A.; Biasoli, S.; Zorzato, P.C.; Ferrari, S.; Lanzo, G.; et al. Pregnancy after Endometriosis: Maternal and Neonatal Outcomes according to the Location of the Disease. Am. J. Perinatol. 2019, 36, 591–598. [CrossRef]

26. Miura, M.; Ushida, T.; Imai, K.; Wang, J.; Moriyama, Y.; Nakano-Kobayashi, T.; Osuka, S.; Kikkawa, F.; Kotani, T. Adverse effects of endometriosis on pregnancy: A case-control study. BMC Pregnancy Childbirth 2019, 19, 373–377. [CrossRef]

27. Berlac, J.F.; Hartwell, D.; Skovlund, C.W.; Langhoff-Roos, J.; Lidegaard, Ø. Endometriosis increases the risk of obstetrical and neonatal complications. Acta Obstet. Gynecol. Scand. 2017, 96, 751–760. [CrossRef]

28. Exacoustos, C.; Lauriola, I.; Lazzeri, L.; De Felice, G.; ZuP, E. Complications during pregnancy and delivery in women with untreated rectovaginal deep infiltrating endometriosis. Fertil. Steril. 2016, 106, 1129–1135.e1. [CrossRef] [PubMed]

29. Matsuzaki, S.; Nagase, Y.; Ueda, Y.; Kakuda, M.; Maeda, M.; Matsuzaki, S.; Kamiura, S. Placenta Previa Complicated with Endometriosis: Contemporary Management, Molecular Mechanisms, and Future Research Opportunities. Biomedicines 2021, 9, 1536. [CrossRef]

30. Page, M.J.; McKenzie, J.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Moher, D. Updating guidance for reporting systematic reviews: Development of the PRISMA 2020 statement. J. Clin. Epidemiol. 2021, 134, 103–112. [CrossRef] [PubMed]

31. Matsuzaki, S.; Jitsumori, M.; Haru, T.; Matsuzaki, S.; Nakagawa, S.; Miyake, T.; Takiuchi, T.; Kikugawa, A.; Kobayashi, E.; Tomimatsu, T.; et al. Systematic review on the needle and suture types for uterine compression sutures: A literature review. BMC Surg. 2019, 19, 196. [CrossRef]

32. Matsuzaki, S.; Takiuchi, T.; Kanagawa, T.; Matsuzaki, S.; Lee, M.; Maeda, M.; Endo, M.; Kimura, T. Maternal and Fetal Outcomes after Prior Mid-Trimester Uterine Rupture: A Systematic Review with Our Experience. Medicina 2021, 57, 1294. [CrossRef]

33. Matsuzaki, S.; Matsuzaki, S.; Chiang, E.J.; Yasukawa, M.; Roman, L.D.; Matsuo, K. Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: A systematic review of literature. Gynecol. Oncol. 2021, 161, 70–77. [CrossRef]

34. Sterne, J.A.C.; Hernán, M.A.; Reeves, B.C.; Savović, J.; Berkman, N.D.; Viswanathan, M.; Henry, D.; Altman, D.G.; Ansari, M.T.; Boutron, I.; et al. ROBINS-I: A tool for assessing the risk of bias in non-randomised studies of interventions. BMJ 2016, 355, i4919. [CrossRef] [PubMed]

35. Sterne, H.J.; Elbers, R.G.; Reeves, B.C.; ROBINS-1 Group. (Eds.) Risk of Bias in Non-Randomized Studies of Interventions (ROBINS-I): Detailed Guidance; ROBINS: Bristol, UK, 2016.

36. Matsuzaki, S.; Lee, M.; Nagase, Y.; Jitsumori, M.; Matsuzaki, S.; Maeda, M.; Takiuchi, T.; Kikugawa, A.; Mimura, K.; Ueda, Y.; et al. A systematic review and meta-analysis of obstetric and maternal outcomes after prior uterine artery embolization. Sci. Rep. 2021, 11, 16914. [CrossRef] [PubMed]

37. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.1, Chapter 10: Analysing Data and Undertaking Meta-analyses. Available online: https://training.cochrane.org/handbook/current/chapter-10 (accessed on 30 November 2021).

38. Matsuzaki, S.; Enomoto, T.; Serada, S.; Yoshino, K.; Nagamori, S.; Morimoto, A.; Yokoyama, T.; Kim, A.; Kimura, T.; Ueda, Y.; et al. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A. Int. J. Cancer 2014, 134, 1796–1809. [CrossRef]

39. Spangmose, A.L.; Ernstad, E.G.; Malchs, S.; Forman, J.; Tiitinen, A.; Gissler, M.; Opdahl, S.; Romundstad, L.B.; Bergh, C.; Wennerholm, U.B.; et al. Obstetric and perinatal risks in 4601 singletons and 884 twins conceived after fresh blastocyst transfers: A Nordic study from the Co, NARTa, S group. Hum. Reprod. 2020, 35, 805–815. [CrossRef] [PubMed]

40. Wennberg, A.L.; Opdahl, S.; Bergh, C.; Henningsen, A.-K.A.; Gissler, M.; Romundstad, L.B.; Pinborg, A.; Tiitinen, A.; Skjærven, R.; Wennerholm, U.-B. Effect of maternal age on maternal and neonatal outcomes after assisted reproductive technology. Fertil. Steril. 2016, 106, 1142–1149.e14. [CrossRef]

41. Ishihara, O.; Araki, R.; Kuwahara, A.; Itakura, A.; Saito, H.; Adamson, G.D. Impact of frozen-thawed single-blastocyst transfer on maternal and neonatal outcome: An analysis of 277,042 single-embryo transfer cycles from 2008 to 2010 in Japan. Fertil. Steril. 2014, 101, 128–133. [CrossRef]

42. Sazonova, A.; Kallen, K.; Thurlin-Kjellberg, A.; Wennerholm, U.-B.; Bergh, C. Obstetric outcome in singletons after in vitro fertilization with cryopreserved/thawed embryos. Hum. Reprod. 2012, 27, 1343–1350. [CrossRef]

43. Wang, Y.; Shi, H.; Chen, L.; Zheng, D.; Long, X.; Zhang, Y. Absolute Risk of Adverse Obstetric Outcomes Among Twin Pregnancy After In Vitro Fertilization by Maternal Age. JAMA Netw. Open 2021, 4, e2123634. [CrossRef]

44. Zargar, M.; Dehdashti, S.; Najafian, M.; Choghababadi, P.M. Pregnancy outcomes following in vitro fertilization using fresh or frozen embryo transfer. JBR&A Reprod. 2021, 25, 570–574. [CrossRef] [PubMed]

45. Hu, K.-L.; Zhang, D.; Li, R. Endometrium preparation and perinatal outcomes in women undergoing single-blastocyst transfer in frozen cycles. Fertil. Steril. 2021, 115, 1487–1494. [CrossRef] [PubMed]

46. Asserhøj, L.L.; Spangmose, A.L.; Henningsen, A.-K.A.; Clausen, T.D.; Ziebe, S.; Jensen, R.B.; Pinborg, A. Adverse obstetric and perinatal outcomes in 1,136 singleton pregnancies conceived after programmed frozen embryo transfer (FET) compared with natural cycle FET. Fertil. Steril. 2021, 115, 947–956. [CrossRef] [PubMed]
47. Wang, J.; Liu, Q.; Deng, B.; Chen, F.; Liu, X.; Cheng, J. Pregnancy outcomes of Chinese women undergoing IVF with embryonic cryopreservation as compared to natural conception. BMC Pregnancy Childbirth 2021, 21, 39. [CrossRef]

48. Epelboin, S.; Labrosse, J.; Fauque, P.; Levi, R.; Gervoiso-Boyer, M.;J.; Devaux, A. Endometriosis and assisted reproductive tech-niques independently related to mother-child morbidity: A French longitudinal national study. Reprod. Biomed. Online 2021, 42, 627–633. [CrossRef]

49. Cochrane, E.; Fando, C.; Kirschen, G.W.; Soucier, D.; Fuchs, A.; Garry, D.J. Assisted reproductive technologies (ART) and placental abnormalities. J. Perinat. Med. 2020, 48, 825–828. [CrossRef]

50. Modest, A.M.; Toth, T.L.; Johnson, K.M.; Shainker, S.A. Placenta Accreta Spectrum: In Vitro Fertilization and Non-In Vitro Fertilization and Placenta Accreta Spectrum in a Massachusetts Cohort. Am. J. Perinatol. 2020, 38, 1533–1539. [CrossRef]

51. Salmanian, B.; Fox, K.A.; Arian, S.E.; Erfani, H.; Clark, S.L.; Aagaard, K.M.; Detlefs, S.E.; Aalipour, S.; Espinoza, J.; Nassr, A.A.; et al. In vitro fertilization as an independent risk factor for placenta accreta spectrum. Am. J. Obstet. Gynecol. 2020, 223, 568.e1–568.e5. [CrossRef]

52. Shinohara, S.; Hirata, S.; Suzuki, K. Association between infertility treatment and intrauterine growth: A multilevel analysis in a retrospective cohort study. BMJ Open 2020, 10, e033675. [CrossRef]

53. Farella, M.; Chanavaz-Lacheray, I.; Verspick, E.; Merlot, B.; Klapczynski, C.; Hennetier, C.; Tuez, J.-R.; Roman, H. Pregnancy outcomes in women with history of surgery for endometriosis. Fertil. Steril. 2020, 113, 996–1004. [CrossRef]

54. Petersen, S.H.; Bergh, C.; Gissler, M.; Åsvold, B.O.; Romundstad, L.B.; Tiitinen, A.; Spangmose, A.L.; Pinborg, A.; Wennerholm, U.O.; et al. Time trends in placenta-mediated pregnancy complications after assisted reproductive technology in the Nordic countries. Am. J. Obstet. Gynecol. 2020, 223, 226.e1–226.e19. [CrossRef] [PubMed]

55. Tanaka, H.; Tanaka, K.; Osato, K.; Kusaka, H.; Maegawa, Y.; Taniguchi, H.; Ikeda, T. Evaluation of Maternal and Neonatal Outcomes of Assisted Reproduction Technology: A Retrospective Cohort Study. Medicina 2020, 56, 32. [CrossRef] [PubMed]

56. Saito, K.; Kuwahara, A.; Ishikawa, T.; Morisaki, N.; Miyado, M.; Fukami, M.; Miyasaka, N.; Ishihara, O.; Irahara, M.; et al. Endometrial preparation methods for frozen-thawed embryo transfer are associated with altered risks of hypertensive disorders of pregnancy, placenta accreta, and gestational diabetes mellitus. Hum. Reprod. 2019, 34, 1567–1575. [CrossRef] [PubMed]

57. Kyozuka, H.; the Japan Environment and Children’s Study (JECS) Group; Yamaguchi, A.; Suzuki, D.; Fujimori, K.; Hosoya, M.; Yasumura, S.; Yokoyama, T.; Sato, A.; Hashimoto, K. Risk factors for placenta accreta spectrum: Findings from the Japan environment and Children’s study. BMC Pregnancy Childbirth 2019, 19, 447. [CrossRef]

58. Santi, E.; Nencini, G.; Cerni, A.; Greco, P.; Spelzini, F.; Tormettino, B.; Scioscia, M. The PLART study: Incidence of preterm labor and adverse pregnancy outcomes after assisted reproductive techniques—a retrospective cohort study. Arch. Gynecol. Obstet. 2019, 300, 911–916. [CrossRef] [PubMed]

59. Nakaya, M.; Ono, M.; Izuka, T.; Kagami, K.; Masumoto, S.; Nakayama, M.; Nakade, K.; Shitano, Y.; Yamazaki, R.; Fujitawa, H. Embryo transfer associated with hormone replacement therapy cycles using assisted reproductive technology increases placenta accreta spectrum. J. Obstet. Gynaecol. Res. 2019, 45, 2394–2399. [CrossRef]

60. Szymusik, I.; Kosinska-Kaczynska, K.; Krowicka, M.; Sep, M.; Marianowski, P.; Wielgos, M. Perinatal outcome of in vitro fertilization singletons—10 years’ experience of one center. Arch. Med. Sci. 2019, 15, 666–672. [CrossRef]

61. Yang, P.; Kang, H.; Ma, C.; Wei, Y.; Tao, L.; Wu, Z. Risk of preterm delivery in singletons conceived by in vitro fertilization. Gynecol. Endocrinol. 2019, 35, 661–664. [CrossRef]

62. Rahu, K.; Allvee, K.; Karro, H.; Rahu, M. Singleton pregnancies after in vitro fertilization in Estonia: A register-based study of complications and adverse outcomes in relation to the maternal socio-demographic background. BMC Pregnancy Childbirth 2019, 19, 51. [CrossRef]

63. Shmueli, A.; Salman, L.; Hiersch, L.; Ashwal, E.; Hadar, E.; Wiznitzer, A.; Yoge, Y.; Aviram, A. Obstetrical and neonatal outcomes of pregnancies complicated by endometriosis. J. Matern. Neonatal Med. 2019, 32, 845–850. [CrossRef] [PubMed]

64. Nirgianakis, K.; Gasparri, M.L.; Radan, A.-P.; Villiger, A.; McKinnon, B.; Mosimann, B.; Papadia, A.; Mueller, M.D. Obstetric complications after laparoscopic excision of posterior deep infiltrating endometriosis: A case–control study. J. Obstet. Gynaecol. Res. 2019, 45, 2394–2399. [CrossRef] [PubMed]

65. Li, H.; Zhu, H.-L.; Chang, X.-H.; Li, Y.; Wang, Y.; Guan, J.; Cui, H. Effects of Previous Laparoscopic Surgical Diagnosis of Endometriosis on Pregnancy Outcomes. Chin. Med. J. 2017, 130, 428–433. [CrossRef] [PubMed]

66. Qin, J.; Sheng, X.; Wu, D.; Gao, S.; You, Y.; Yang, T. Adverse Obstetric Outcomes Associated With In Vitro Fertilization in Singleton Pregnancies. Reprod. Sci. 2017, 24, 595–608. [CrossRef] [PubMed]

67. Shu, L.; Zhang, Y.; Liu, Y.; Zhang, R.; Wu, Y.; Huang, Y.; Liu, F.; Linling, Z.; Sun, S.; Xing, L.; et al. Maternal and Live-birth Outcomes of Assisted Reproduction Technology: A Retrospective Cohort Study. Sci. Rep. 2016, 6, 35141. [CrossRef] [PubMed]
94. Harada, T.; Taniguchi, F.; Onishi, K.; Kurozawa, Y.; Hayashi, K.; Harada, T.; Japan Environment & Children’s Study Group. Obstetrical Complications in Women with Endometriosis: A Cohort Study in Japan. *PLoS ONE* **2016**, *11*, e0168476. [CrossRef] [PubMed]

95. Yi, K.W.; Cho, G.J.; Park, K.V.; Han, S.W.; Shin, J.-H.; Kim, T.; Hur, J.-Y. Endometriosis Is Associated with Adverse Pregnancy Outcomes: A National Population-Based Study. *Reprod. Sci.* **2020**, *27*, 1175–1180. [CrossRef]

96. Opone, H.K.; Fedorcsak, P.; Omland, A.K.; Abyholm, T.; Bjercce, S.; Ertzeid, G.; Oldereid, N.; Mellembakken, J.R.; Tanbo, T. In vitro fertilization is a successful treatment in endometriosis-associated infertility. *Fertil. Steril.* **2012**, *97*, 912–918. [CrossRef] [PubMed]

97. Gasparri, M.L.; Nirgianakis, K.; Taghavi, K.; Papadia, A.; Mueller, M.D. Placenta previa and placental abruption after assisted re-productive technology in patients with endometriosis: A systematic review and meta-analysis. *Arch. Gynecol. Obstet.* **2018**, *298*, 27–34. [CrossRef] [PubMed]

98. Leone Roberti Maggiore, U.; Ferrero, S.; Bergamini, A.; Inversetti, A.; Giorgione, V. A systematic review on endometriosis during pregnancy: Diagnosis, misdiagnosis, complications and outcomes. *Hum. Reprod. Update* **2016**, *22*, 70–103. [CrossRef]

99. Shih, J.C.; Kang, J.; Tsai, S.J.; Lee, J.K.; Liu, K.L.; Huang, K.Y. The “rain sign”: An ultrasound finding in placenta accreta spectrum indi-cating deep villous invasion and adverse outcomes. *Am. J. Obstet. Gynecol.* **2021**, *225*, 292.e1–292.e17. [CrossRef]

100. Collins, S.L.; Alemdar, B.; van Beehkuizen, H.J.; Bertholdt, C.; Braun, T.; Calda, P.; Delorme, P.; Duvekot, J.J.; Gronbeck, L.; Kayem, G.; et al. Evidence-based guidelines for the management of abnormally invasive placenta: Recommendations from the International Society for Abnormally Invasive Placenta. *Am. J. Obstet. Gynecol.* **2019**, *220*, 511–526. [CrossRef]

101. Iacovelli, A.; Liberati, M.; Khalil, A.; Timor-Trisch, I.; Leonbroni, M.; Buca, D.; Milanì, M.; Flacco, M.E.; Manzoli, L.; Fanfani, F.; et al. Risk factors for abnormally invasive placenta: A systematic review and meta-analysis. *J. Matern. Neonatal Med.* **2018**, *33*, 471–481. [CrossRef] [PubMed]

102. Olive, D.L.; Pritts, E.A. Treatment of endometriosis. *N. Engl. J. Med.* **2001**, *345*, 266–275. [CrossRef]

103. Glavind, M.T.; Forman, A.; Arendt, L.H.; Nielsen, K.; Henriksen, T.B. Endometriosis and pregnancy complications: A Danish cohort study. *Fertil. Steril.* **2017**, *107*, 160–166. [CrossRef] [PubMed]

104. Stephansson, O.; Kieler, H.; Granath, F.; Falconer, H. Endometriosis, assisted reproduction technology, and risk of adverse pregnancy outcome. *Hum. Reprod.* **2009**, *24*, 2341–2347. [CrossRef] [PubMed]

105. Mannini, L.; Sorbi, F.; Noci, I.; Ghizzoni, V.; Perelli, F.; Di Tommaso, M.; Mattei, A.; Fambrini, M. New adverse obstetrics outcomes associated with endometriosis: A retrospective cohort study. *Arch. Gynecol. Obstet.* **2017**, *295*, 141–151. [CrossRef] [PubMed]

106. Roque, M.; Valle, M.; Sampaio, M.; Geber, S. Obstetric outcomes after fresh versus frozen-thawed embryo transfers: A systematic review and meta-analysis. *JBR A Assist. Reprod.* **2018**, *22*, 253–260. [CrossRef]

107. Liu, X.; Shi, W.; Shi, J. Natural cycle frozen-thawed embryo transfer in young women with regular menstrual cycles increases the live-birth rates compared with hormone replacement treatment: A retrospective cohort study. *Fertil. Steril.* **2020**, *113*, 811–817. [CrossRef]

108. Pang, C.; Guo, L.; Bi, Y.; Wang, K.; Lian, F.; Wu, Z. A comparison of pregnancy rate between natural cycle and hormone re-placement cycle in patients who underwent frozen embryo transfer using 2 consecutive hormone replacement regimens: A STROBE-compliant retrospective study. *Medicine* **2020**, *99*, e22163. [CrossRef]

109. Tikkkanen, M.; Paavonen, J.; Loukovaara, M.; Stefanovic, V. Antenatal diagnosis of placenta accreta leads to reduced blood loss. *Acta Obstet. Gynecol. Scand.* **2011**, *90*, 1140–1146. [CrossRef] [PubMed]

110. Warshak, C.R.; Ramos, G.A.; Eskander, R.; Benirschke, K.; Saenz, C.C.; Kelly, T.F.; Moore, T.R.; Resnik, R. Effect of Predelivery Diagnosis in 99 Consecutive Cases of Placenta Accreta. *Obstet. Gynecol.* **2010**, *115*, 65–69. [CrossRef]

111. Bouvier, A.; Sentilhes, L.; Thouveny, F.; Bouet, P.-E.; Gillard, P.; Willoteaux, S.; Aubé, C. Planned caesarean in the interventional radiology cath lab to enable immediate uterine artery embolization for the conservative treatment of placenta accreta. *Clin. Radiol.* **2012**, *67*, 1089–1094. [CrossRef]

112. Nagase, Y.; Matsuizaki, S.; Endo, M.; Hara, T.; Okada, A.; Mimura, K.; Hiramatsu, K.; Kakigano, A.; Nakatsuka, E.; Miyake, T.; et al. Placenta previa with posterior extrauterine adhesion: Clinical features and management practice. *BMJ Surg.* **2021**, *10*, 10. [CrossRef] [PubMed]

113. Sentilhes, L.; Ambrosetti, C.; Kayem, G.; Provansal, M.; Fernandez, H.; Perrotin, F.; Winer, N.; Pierre, F.; Benachi, A.; Dreyfus, M.; et al. Maternal Outcome After Conservative Management of Placenta Accreta. *Obstet. Gynecol.* **2010**, *115*, 526–534. [CrossRef] [PubMed]

114. Matsuzaki, S.; Grubbs, B.H.; Matsuo, K. Delayed hysterectomy versus continuing conservative management for placenta percreta: Which is better? *Am. J. Obstet. Gynecol.* **2020**, *222*, 304. [CrossRef] [PubMed]

115. Sentilhes, L.; Seco, A.; Azria, E.; Beucher, G.; Bonnet, M.P.; Branger, B.; Carbillon, L.; Chiesa, C.; Hebert, C.C.; Dreyfus, M.; et al. Conservative Management or Cesarean Hysterectomy for Placenta Accreta Spectrum: The PACCRETA Prospective Study. *Am. J. Obstet. Gynecol.* **2021**, in press. [CrossRef] [PubMed]